These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11920277)

  • 21. Rituximab-induced tumor progression: does it really happen?
    Ozguroglu M; Turna H
    Med Oncol; 2004; 21(2):205-6. PubMed ID: 15299193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
    Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
    Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
    Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
    Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
    Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
    J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
    Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
    Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
    Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
    Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
    Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
    Gutiérrez-García G; Colomo L; Villamor N; Arenillas L; Martínez A; Cardesa T; García-Herrera A; Setoain X; Rodríguez S; Ghita G; Abrisqueta P; Giné E; Bosch F; Campo E; Montserrat E; López-Guillermo A
    Leuk Lymphoma; 2010 Jul; 51(7):1225-32. PubMed ID: 20497002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
    Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
    Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.
    Ngo L; Hee SW; Lim LC; Tao M; Quek R; Yap SP; Loong EL; Sng I; Hwan-Cheong TL; Ang MK; Ngeow J; Tham CK; Tan MH; Lim ST
    Leuk Lymphoma; 2008 Mar; 49(3):462-9. PubMed ID: 18297522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
    Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
    Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
    Jetsrisuparb A; Wiangnon S; Komvilaisak P; Kularbkaew C; Yutanawiboonchai W; Mairieng E
    J Pediatr Hematol Oncol; 2005 Apr; 27(4):223-6. PubMed ID: 15838396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement activation plays a key role in the side-effects of rituximab treatment.
    van der Kolk LE; Grillo-López AJ; Baars JW; Hack CE; van Oers MH
    Br J Haematol; 2001 Dec; 115(4):807-11. PubMed ID: 11843813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.